Cost Containment Measures Hurting Drugmaker Revenue Earning Opportunities

BMI View: We believe the Spanish government's decision to implement further austerity measures is a necessary and prudent course of action. The country still has the third highest budget deficit in the eurozone and continues to receive negative attention from bond markets. However, its decision to further target the pharmaceuticals and healthcare sector will not sit well with drug companies - as the overall austerity measures have a crimping effect of on overall economic growth in Spain, cost containment within the healthcare sector will significantly affect the revenue-earning opportunities for

To read the full article, please choose one of the following options: